Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cometriq cabozantinib: Phase III started

Exelixis began the open-label, international Phase III METEOR trial to compare 60 mg oral cabozantinib

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE